FOSUN 复星

復星國際有限公司
FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF CERTAIN SHARES IN A SUBSIDIARY

THE DISPOSAL

On 4 September 2026 (India time), Fosun Pharma Singapore, an indirect subsidiary of the Company, disposed of an aggregate of 9,897,000 shares of the Target Company (representing approximately 6.00% of the total shares of the Target Company) through block trades and open market bidding. The aggregate consideration of the Disposal is approximately INR27.996 billion (including transaction costs, equivalent to approximately USD0.294 billion), and the average price per share is approximately INR2,828.78 (including transaction costs). Prior to and upon completion of the Disposal, the Group held 51.76% and 45.76% equity interest in the Target Company, respectively. Upon completion of the Disposal, the Target Company remains a subsidiary of Fosun Pharma and the Company.

LISTING RULE IMPLICATIONS

As one or more applicable percentage ratios (as defined under Rule 14.04(9) of the Listing Rules) in relation to the Disposal exceed 5% but all are less than 25%, the Disposal constitutes a discloseable transaction of the Company and is subject to notification and announcement requirements under Chapter 14 of the Listing Rules.

The Disposal was conducted through block trades and open market bidding on the stock exchanges of India, with UBS Securities India Private Limited and BNP Paribas Securities India Private Limited acting as Placing Agents. Based on the current information available and to the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the Placing Agents, the market buyers under the block trades and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons. For the shares of the Target Company disposed of through open market bidding, the identities of the buyers could not be ascertained. In the event that the Company becomes aware that any market buyer of the Disposal is a connected person of the Company, the Company will comply with the applicable reporting, announcement and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules (if any) as and when appropriate.

THE DISPOSAL

On 4 September 2026 (India time), Fosun Pharma Singapore, an indirect subsidiary of the Company, disposed of an aggregate of 9,897,000 shares of the Target Company (representing approximately 6.00% of the total shares of the Target Company) through block trades and open market bidding. The aggregate consideration of the Disposal is approximately INR27.996 billion (including transaction costs, equivalent to approximately USD0.294 billion), and the average price per share is approximately INR2,828.78 (including transaction costs). Prior to and upon completion of the Disposal, the Group held 51.76% and 45.76% equity interest in the Target Company, respectively. Upon completion of the Disposal, the Target Company remains a subsidiary of Fosun Pharma and the Company.

Total Consideration

The aggregate consideration of the Disposal is approximately INR27.996 billion (including transaction costs, equivalent to approximately USD 0.294 billion).

The consideration of the Disposal was determined at the time of the relevant transactions through the block trades and open market bidding on the stock exchanges of India at an average price of approximately INR2,828.78 per share (including transaction costs), representing a discount of approximately 2.72% to the previous closing price (i.e. INR2,907.90). The consideration of the Disposal will be received by Fosun Pharma Singapore in cash upon settlement, after deducting applicable taxes and charges.

FINANCIAL IMPLICATIONS OF THE DISPOSAL

Upon completion of the Disposal, the Target Company remains a subsidiary of Fosun Pharma and the Company, and its financial statements will continue to be consolidated into Fosun Pharma and the Company's consolidated financial statements, respectively. Accordingly, the Disposal is not expected to result in the recognition of any gain or loss to the Company. The actual financial impact is subject to the audit results.

REASONS FOR AND BENEFITS OF THE DISPOSAL AND USE OF PROCEEDS

The proceeds from the Disposal will be mainly applied to Fosun Pharma Group's research and development investment, the funding of its share repurchases, and the repayment of its interest-bearing borrowings, etc. The proceeds from the Disposal will enhance the net assets of the Fosun Pharma Group, consisting of members of the Group.

The Directors (including the independent non-executive Directors) consider that the terms of the Disposal are fair and reasonable, and in the interests of the Company and its Shareholders as a whole.

GENERAL INFORMATION

The Company

The Company is a global innovation-driven consumer group with mission to provide high quality products and services for families around the world in health, happiness, wealth and intelligent manufacturing segments.

Fosun Pharma Singapore

Fosun Pharma Singapore is a limited liability company incorporated under the laws of Singapore, and is a wholly-owned subsidiary and one of the overseas operating entities of Fosun Pharma as at the date of this announcement. Fosun Pharma is a subsidiary of the Company and its H shares and A shares are listed and traded on the Main Board of the Hong Kong Stock Exchange with stock code 02196 and the Shanghai Stock Exchange with stock code 600196, respectively. As an innovation-driven global pharmaceutical and healthcare group, Fosun Pharma Group deeply engaged in the pharmaceutical business, with innovative drugs as its key development focus, and directly operates medical devices and medical diagnostics, as well as healthcare health services business.

The Target Company

The Target Company is a company incorporated under the laws of India and is a subsidiary of Fosun Pharma and the Company. It is principally engaged in the manufacturing of injectable drugs and its shares are listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND.

The consolidated net profit (both before and after taxation) of the Target Company for the two financial years (i.e. for the two financial years ended 31 March 2025 and 31 March 2026 prepared in accordance with Indian Accounting Standards) immediately preceding the Disposal are as follows:

	For the year ended 31 March	
	2025	**2026**
	(audited)	**(audited)**
	approximately	**approximately**
	INR million	**INR million**
Net profit before tax	10,626.58	14,645.80
Net profit after tax	6,985.26	10,273.16

The audited consolidated net asset value as at 31 March 2026 of the Target Company (prepared in accordance with Indian Accounting Standards) was approximately INR103,579.50 million (equivalent to approximately USD1,085.97 million).

LISTING RULE IMPLICATIONS

As one or more applicable percentage ratios (as defined under Rule 14.04(9) of the Listing Rules) in relation to the Disposal exceed 5% but all are less than 25%, the Disposal constitutes a discloseable transaction of the Company and is subject to notification and announcement requirements under Chapter 14 of the Listing Rules.

The Disposal was conducted through block trades and open market bidding on the stock exchanges of India, with UBS Securities India Private Limited and BNP Paribas Securities India Private Limited acting as Placing Agents. Based on the current information available and to the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the Placing Agents, the market buyers under the block trades and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons. For the shares of the Target Company disposed of through open market bidding, the identities of the buyers could not be ascertained. In the event that the Company becomes aware that any market buyer of the Disposal is a connected person of the Company, the Company will comply with the applicable reporting, announcement and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules (if any) as and when appropriate.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings as set out below:

"Board"	the board of directors of the Company
"Company"	Fosun International Limited, a company incorporated in Hong Kong with limited liability and whose shares are listed and traded on the Main Board of the Hong Kong Stock Exchange with stock code 00656
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Disposal"	the disposal by Fosun Pharma Singapore of an aggregate of 9,897,000 shares of the Target Company through block trades and open market bidding on 4 September 2026 (India time)
"Fosun Pharma"	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司), a joint stock company established in the PRC with limited liability, the H Shares and A Shares of which are listed and traded on the Main Board of the Hong Kong Stock Exchange with stock code 02196 and the Shanghai Stock Exchange with stock code 600196, respectively
"Fosun Pharma Group"	Fosun Pharma and its subsidiaries
"Fosun Pharma Singapore"	Fosun Pharma Industrial Pte. Ltd., a company incorporated under the laws of Singapore, which is a wholly-owned subsidiary of Fosun Pharma
"Group"	the Company and its subsidiaries
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited
"INR"	Rupees, the lawful currency of India and INR1 is equivalent to approximately USD0.010484, based on the INR/USD exchange rate published by the State Administration of Foreign Exchange of the PRC in *Rates*

	of Exchange Between Various Currencies and the US Dollar (31 August 2026)
"Listing Rules"	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange
"Placing Agents"	UBS Securities India Private Limited and BNP Paribas Securities India Private Limited
"PRC"	the People's Republic of China and, for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region and Taiwan region of the PRC
"Shareholder(s)"	the shareholder(s) of the Company
"Target Company"	Gland Pharma Limited, a company incorporated under the laws of India, the shares of which are listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND
"USD"	United States dollars, the lawful currency of the United States
"%"	per cent

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

6 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Huang Zhen and Mr. Pan Donghui; the non-executive directors are Mr. Li Fuhua and Mr. Luo Yuanli; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Dr. Lee Kai-Fu and Ms. Tsang King Suen Katherine.

* *for identification purposes only.*